Valuation: Exelixis, Inc.

Market Cap 14.47B 75.73B 12.85B 12B 10.94B 20.62B 1,391B 20.82B 145B 56.26B 711B 54.32B 53.14B 2,282B P/E 2026 *
18x
P/E 2027 * 14.9x
Enterprise Value 13.72B 71.84B 12.19B 11.38B 10.37B 19.56B 1,319B 19.75B 138B 53.37B 674B 51.52B 50.41B 2,164B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 4.42x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+0.44%
Current month+0.44%
1 month+0.44%
3 months+2.66%
6 months+26.47%
Current year+14.89%
Current year 104.72
Extreme 104.72
140.56
1 year 98.24
Extreme 98.24
140.56
3 years 50.71
Extreme 50.71
140.56
5 years 40
Extreme 40
140.56
10 years 40
Extreme 40
140.56
Manager TitleAgeSince
Chief Executive Officer 65 21/07/2010
Director of Finance/CFO 58 14/07/2015
Chief Operating Officer 63 31/01/2016
Director TitleAgeSince
Director/Board Member 70 31/01/2004
Director/Board Member 82 31/07/2004
Chairman 77 31/12/1997
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+0.44% - - 14.47B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.23%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.11%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 2.55B 13.37B 2.27B 2.12B 1.93B 3.64B 246B 3.68B 25.64B 9.93B 126B 9.59B 9.38B 403B 2.91B 15.21B 2.58B 2.41B 2.2B 4.14B 279B 4.18B 29.16B 11.3B 143B 10.91B 10.67B 458B
Net income 821M 4.3B 729M 681M 620M 1.17B 78.89B 1.18B 8.24B 3.19B 40.33B 3.08B 3.01B 129B 1.01B 5.3B 899M 840M 765M 1.44B 97.32B 1.46B 10.16B 3.94B 49.75B 3.8B 3.72B 160B
Net Debt -744M -3.9B -661M -617M -563M -1.06B -71.57B -1.07B -7.47B -2.9B -36.59B -2.8B -2.73B -117B -1.62B -8.49B -1.44B -1.35B -1.23B -2.31B -156B -2.33B -16.28B -6.31B -79.75B -6.09B -5.96B -256B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.39USD
Average target price
53.93USD
Spread / Average Target
-7.63%

Quarterly revenue - Rate of surprise